Takeda Asks Japanese Regulators to Approve Vedolizumab as an Ulcerative Colitis Treatment

Takeda Asks Japanese Regulators to Approve Vedolizumab as an Ulcerative Colitis Treatment
Takeda Pharmaceutical Company has submitted a new drug application to Japanese regulators for vedolizumab (MLN0002) as a treatment for adults with moderate to severe ulcerative colitis. Ulcerative colitis "is a chronic, progressive inflammatory disease of the large intestine, which typically affects young adults," Toshiro Heya, head of Takeda Development Center Japan, said in a press release. "The disease has a high impact on their quality of life, with symptoms including diarrhea, rectal bleeding, incontinence and abdominal pain. Through this
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *